Letter to the Editor

Autoradiography of [3H]Aspartate and Glutamate Transport in Schizophrenia

Vladimir J Balcar*[1,2] and Ellas K Nanitsos[2]

[1]*Institute for Biomedical Research, The University of Sydney, Sydney, NSW, Australia;* [2]*School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia*

Sir

Quantitative autoradiography is uniquely useful in being able to show the distribution of important binding sites *in situ*, at the same time providing information on their affinities and pharmacological profiles. The results are, however, strongly influenced by the choice of radioligands. This is particularly relevant for the studies of glutamate transport (Scarr *et al*, 2005).

GLAST (EAAT1) and GLT (EAAT2) are by far the most abundant excitatory amino-acid transporters (EAAT's) in the CNS (see for reviews, Danbolt, 2001; Shigeri *et al*, 2004). The principal EAAT in forebrain regions is GLT while GLAST predominates in cerebellum (see for review, Danbolt, 2001). The regional distribution of [3H]aspartate-marked sites as studied by autoradiography therefore differs from that of GLT but is remarkably similar to that of GLAST (cerebellar cortex ⩾ forebrain structures: Killinger *et al*, 1996; Balcar *et al*, 2001; Takamoto *et al*, 2002; Balcar, 2002).

D-Aspartate (Davies and Johnston, 1976) has long been used as a radioligand in autoradiographic studies (Parsons and Rainbow, 1983; see for reviews, Balcar *et al*, 2001; Balcar, 2002) mainly because Na^+-dependent glutamate transport was thought to have about equal affinity for L- (not D-) glutamate, L-aspartate or D-aspartate ('stereoselective anomaly'; Cooper *et al*, 1998; Balcar *et al*, 2001; Balcar, 2002). However, assumption that [3H]aspartate, in the presence of Na^+, would always label equally well all EAAT's may not be correct. Affinities of L- and D-aspartate for the [3H]aspartate-labelled binding sites are about 50 times greater $(IC_{50} < 1 \mu M)$ than the corresponding affinity of L-glutamate (Balcar *et al*, 2001; Takamoto *et al*, 2002) and greater than the affinities of glutamate and aspartate in uptake/transport studies (see for reviews, Bridges *et al*, 1999; Danbolt, 2001; Balcar *et al*, 2001). The high affinity makes [3H]aspartate a convenient radioligand producing adequate labelling at low concentrations. However, neither the regional distribution of [3H]-aspartate binding nor, indeed, its substrate specificity, suggest that it labels preferentially GLT (Bridges *et al*, 1999; Balcar *et al*, 2001). If [3H]D-aspartate labels mostly a variant of GLAST (Takamoto *et al*, 2002), the autoradiography could severely underestimate the most abundant EAAT (GLT), particularly at the glutamatergic synapses in the cerebral cortex (Minelli *et al*, 2001, Sullivan *et al*, 2004).

Glutamate transport may be altered in schizophrenia: chronic neuroleptics reduce glutamate transport (Schneider *et al*, 1998; De Souza *et al*, 1999, Schmitt *et al*, 2003; see for review, Balcar and Nanitsos, 2005) while increased levels of EAAT's have been reported in post mortem schizophrenic brains from nonmedicated patients (Matute *et al*, 2005). Most of the changes, however, affect GLT—not GLAST—particularly in the cerebral cortex (rat: 70% reduction by chronic clozapine, Melone *et al*, 2001, 2003; humans: GLT in tissue from patients with schizophrenia 2–4 times greater, compared to controls, Matute *et al*, 2005). Given that binding experiments using 40 nM [3H]D-aspartate (Scarr *et al*, 2005) may not adequately label the most important glutamate transporter in the cerebral cortex (GLT), suggesting that glutamate transport in cortical areas affected by schizophrenia is not changed (Scarr *et al*, 2005) seems premature.

*Correspondence: Dr VJ Balcar, Anatomy and Histology, Institute for Biomedical Research and School of Medical Sciences, Anderson Stuart Building F 13, The University of Sydney, Sydney NSW 2006, Australia, Tel: +61 2 9351 2837, Fax: +61 2 9351 2813,
E-mail: vibar@anatomy.usyd.edu.au

REFERENCES

Balcar VJ (2002). Molecular pharmacology of the Na^+-dependent transport of acidic amino acids in the mammalian central nervous system. *Biol Pharm Bull* **25**: 291–301.

Balcar VJ, Nanitsos EK (2005). Glutamate transport—target for the next generation of neuroleptics? *Psychiatry (Prague)* **29**: S1, 19–23.

Balcar VJ, Takamoto A, Yoneda Y (2001). Neurochemistry of L-glutamate transport in the CNS: a review of thirty years of progress. *Collect Czech Chem Commun* **66**: 1315–1340.

Bridges RJ, Kavanaugh MP, Chamberlin AR (1999). A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system. *Curr Pharm Design* **5**: 363–379.

Cooper B, Chebib M, Shen J, King NJC, Darvey IG, Kuchel PW *et al* (1998). Structural selectivity and molecular nature of L-glutamate transport in cultured human fibroblasts. *Arch Biochem Biophys* **353**: 356–364.

Danbolt NC (2001). Glutamate uptake. *Prog Neurobiol* **65**: 1–105.

Davies LP, Johnston GAR (1976). Uptake and release of D- and L-aspartate by rat brain slices. *J Neurochem* **26**: 1007–1014.

De Souza IE, McBean GJ, Meredith GE (1999). Chronic haloperidol treatment impairs glutamate transport in the rat striatum. *Eur J Pharmacol* **382**: 139–142.

Killinger S, Blume GL, Bohart L, Bested A, Dias LS, Cooper B *et al* (1996). Autoradiographic studies indicate regional variation in the characteristics of L-glutamate transporters in the rat brain. *Neurosci Lett* **216**: 101–104.

Matute C, Melone M, Vallejo-Illarramendi A, Conti F (2005). Increased expression of the astrocytic glutamate transporter GLT in the prefrontal cortex of schizophrenics. *Glia* **49**: 451–455.

Melone M, Bragina L, Conti F (2003). Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. *Mol Psychiatr* **8**: 12–13.

Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Perez-Samartin A, Matute C, Cozzi A *et al* (2001). The expression of glutamate transporter GLT in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. *Mol Psychiatr* **6**: 380–386.

Minelli A, Barbaresi P, Reimer RJ, Edwards RJ, Conti F (2001). The glial glutamate transporter GLT is localized both in the vicinity and at a distance from axon terminals in the rat cerebral cortex. *Neuroscience* **108**: 51–59.

Parsons B, Rainbow TC (1983). Quantitative autoradiography of sodium dependent [^{3}H]D-aspartate binding sites in rat brain. *Neurosci Lett* **36**: 365–402.

Scarr E, Beneyto M, Meador-Woodruff JH, Dean B (2005). Cortical glutamatergic markers in schizophrenia. *Neuropsychopharmacology* **30**: 1521–1531.

Schmitt A, Zink M, Petroianu G, May B, Brans DF, Henn FA (2003). Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. *Neurosci Lett* **347**: 81–84.

Schneider JS, Wade T, Lidsky TI (1998). Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. *Neuroreport* **9**: 133–136.

Shigeri Y, Seal RP, Shimamoto K (2004). Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. *Brain Res Rev* **45**: 250–265.

Sullivan R, Rauen T, Fischer F, Wießner M, Grewer C, Bicho A *et al* (2004). Cloning, transport properties and differential localization of two splice variants of GLT-1 in the rat CNS: Implications for CNS glutamate homeostasis. *Glia* **45**: 155–169.

Takamoto A, Quiggin LB, Lieb I, Shave E, Balcar VJ, Yoneda Y (2002). Differences between D- and L-aspartate binding to the Na$^+$-dependent binding sites on glutamate transporters in frozen sections of rat brain. *Life Sci* **70**: 991–1001.